Identifying the stable polymorph early in the drug discovery-development process

Pharmaceutical Development and Technology

Volumn 10, Issue 2, 2005, Pages 291-297

  Miller, Jonathan M ^a   Collman, Benjamin M ^a   Greene, Landon R ^a   Grant, David J W ^b   Blackburn, Anthony C ^a  

^a Ann Arbor Laboratories   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Crystallization; Polymorph screening; Polymorphs; Ritonavir; Solubility; Solvent mediated polymorphic transformation; Stable polymorph

Indexed keywords

CHEMICAL COMPOUND; COMPOUND A; RITONAVIR; SOLVENT; UNCLASSIFIED DRUG;

ARTICLE; CRYSTALLIZATION; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; GRAVIMETRY; PRIORITY JOURNAL;

ANTI-HIV AGENTS; DRUG DESIGN; ISOMERISM; PHARMACEUTICAL PREPARATIONS; PHARMACEUTICAL SOLUTIONS; RITONAVIR; SOLVENTS; SPECTRUM ANALYSIS, RAMAN; THERMODYNAMICS; X-RAY DIFFRACTION;

EID: 18744373010     PISSN: 10837450     EISSN: None     Source Type: Journal    
DOI: 10.1081/PDT-200054467     Document Type: Article

References (12)

1. Bernstein, J. Polymorphism in Molecular Crystals; Oxford University Press: Oxford, 2002.
2. Threlfall, T.L. Analysis of organic polymorphs. A review. Analyst 1995, 120, 2435-2460.
3. Grant, D.J.W. Theory and origin of polymorphism. In Polymorphism in Pharmaceutical Solids; Brittain, H.G., Ed.; Marcel Dekker: New York, 1999; 1-33.
4. Chemburkar, S.R.; Bauer, J.; Deming, K.; Spiwek, H.; Patel, K.; Morris, J.; Henry, R.; Spanton, S.; Dziki, W.; Porter, W.; Quick, J.; Bauer, P.; Donaubauer, J.; Narayanan, B.A.; Soldani, M.; Riley, D.; McFarland, K. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Org. Process Res. Dev. 2000, 4, 413-417.
5. Guillory, J.K. Generation of polymorphs, hydrates, solvates, and amorphous solids. In Polymorphism in Pharmaceutical Solids; Brittain, H.G., Ed.; Marcel Dekker: New York, 1999; 183-226.
6. Mullin, J.W. Crystallization, 3rd Ed.; Butterworth-Heineman: Oxford, 1993.
7. Ostwald, W. Studien Uber Die Bildung und Umwandlung Fester Korper. Z. Physik. Chem. 1897, 22, 289-302.
8. Rodriguez-Hornedo, N.; Murphy, D. Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J. Pharm. Sci. 1999, 88, 651-660.
9. Gu, C.; Young, V., Jr.; Grant, D.J.W. Polymorph screening: influence of solvents on the rate of solvent-mediated polymorphic transformation. J. Pharm. Sci. 2001, 90, 1878-1890.
10. Morissette, S.L.; Soukasene, S.; Levinson, D.; Cima, M.J.; Almarsson, O. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization. Proc. Natl. Acad. Sci. 2003, 100, 2180-2184.
11. Bauer, J.; Spanton, S.; Henry, R.; Quick, J.; Dziki, W.; Porter, W.; Morris, J. Ritonavir: an extraordinary example of conformational polymorphism. Pharm. Res. 2001, 18, 859-866.
12. Gu, C.; Chatterjee, K.; Young, V., Jr.; Grant, D.J.W. Stabilization of a metastable polymorph of sulfamerazine by structurally related additives. J. Cryst. Growth 2002, 235, 471-481.